Tirzepatide acts as a GIP analog, meaning it mimics the actions of GIP to further improve insulin release
Ongoing research may teach us more about whether GLP-1 receptor agonists can influence Alzheimers disease progression or neurodegenerative risk
Here is the financial tear-down of the math behind mass adoption, followed by a forensic FAQ addressing the most critical questions surrounding GLP-1 pricing
Despite the convenience of oral administration, subcutaneous versions are, and will remain, fundamentally more efficacious than their oral counterparts, and their production will be more cost-efficient due to significantly lower API requirements
But we want all of our active pharmaceutical ingredients that come into this state to be of high quality, regardless of whether its a weight-loss drug or hormone-replacement therapy or anything else. Continuing innovation As Lilly prepares for the release of its own oral weight-loss drug, orforglipron, the company is looking to ensure it does not experience the same shortages it did in the early days of Mounjaro and Zepbound
International guidelines recommend the use of GLP-1 analogues in T2DM patients with ASCVD or who have high cardiovascular risk [44, 45]
